Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18392406 | 1.00 | MCL1 (1.00) | MCL1BCL2L1 | |
| SCHEMBL18392310 | 0.86 | MCL1 (0.85) | MCL1BCL2L1 | |
| SCHEMBL30076624 | 0.86 | MCL1 (0.85) | MCL1BCL2L1 | |
| SCHEMBL29540152 | 0.84 | MCL1 (1.00) | MCL1BCL2L1 | |
| SCHEMBL18392259 | 0.84 | MCL1 (1.00) | MCL1BCL2L1 | |
| SCHEMBL29540209 | 0.83 | MCL1 (1.00) | MCL1BCL2L1 | |
| SCHEMBL29539751 | 0.83 | MCL1 (1.00) | MCL1BCL2L1 | |
| SCHEMBL29539977 | 0.83 | MCL1 (1.00) | MCL1BCL2L1 | |
| SCHEMBL18392262 | 0.83 | MCL1 (1.00) | MCL1BCL2L1 | |
| SCHEMBL18392238 | 0.83 | MCL1 (1.00) | MCL1BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | UNIV MARYLAND (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3319938-B1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEREOF | UNIV MARYLAND (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396549-A1 | SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF | MCL1, TP53, MYC | MCL1 1/4885BCL2L1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.